Miniaturized Smart Sensor Device for the Detection of Hypo- and Hyperglycemic Events in Persons Diagnosed With Diabetes
The study, sponsored by Indiana University, aims to develop a miniaturized smart sensor device capable of noninvasively detecting hypo- and hyperglycemic events in diabetic patients through the analysis of VOCs in exhaled breath. This innovative approach could potentially disrupt the diabetes management market by providing a non-invasive alternative to traditional blood glucose monitoring methods. The target demographic includes children and young adults aged 7-25 with Type 1 and Type 2 diabetes, a segment that represents a significant portion of the diabetes population. If successful, this technology could enhance patient compliance and improve glycemic control, thereby addressing a critical need in diabetes care. The competitive landscape includes established continuous glucose monitoring (CGM) systems, but the non-invasive nature of this device may offer a unique selling proposition. Diligence should focus on regulatory pathways, potential partnerships for commercialization, and the scalability of manufacturing the sensor device.
Indication: Diabetes
Modality: medical device
Target: Volatile Organic Compounds (VOCs) in exhaled breath associated with glycemic events.
Sponsor: Indiana University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 14, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Volatile Organic Compounds (VOCs) in exhaled breath associated with glycemic events.
View original source fields
Condition raw: Diabetes, Hyperglycemia, Hypoglycemia (Diabetic)
Condition normalized: Diabetes, Hyperglycemia, Hypoglycemia (Diabetic)
Modality raw: medical device
Modality normalized: medical device
Target raw: Volatile Organic Compounds (VOCs) in exhaled breath associated with glycemic events.
Target normalized: Volatile Organic Compounds (VOCs) in exhaled breath associated with glycemic events.